[go: up one dir, main page]

AU2003269257A8 - Regulation of cap-1 - Google Patents

Regulation of cap-1

Info

Publication number
AU2003269257A8
AU2003269257A8 AU2003269257A AU2003269257A AU2003269257A8 AU 2003269257 A8 AU2003269257 A8 AU 2003269257A8 AU 2003269257 A AU2003269257 A AU 2003269257A AU 2003269257 A AU2003269257 A AU 2003269257A AU 2003269257 A8 AU2003269257 A8 AU 2003269257A8
Authority
AU
Australia
Prior art keywords
regulation
cap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003269257A
Other versions
AU2003269257A1 (en
Inventor
Kevin Bruce Bacon
Herath Mudiyanselage At Herath
Ningshu Liu
Peter Reinemer
Christian Rohlff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Oxford Glycosciences UK Ltd
Original Assignee
Bayer Healthcare AG
Oxford Glycosciences UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG, Oxford Glycosciences UK Ltd filed Critical Bayer Healthcare AG
Publication of AU2003269257A8 publication Critical patent/AU2003269257A8/en
Publication of AU2003269257A1 publication Critical patent/AU2003269257A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003269257A 2002-10-08 2003-10-08 Use of cap-1 for the therapy of asthma Abandoned AU2003269257A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0223272A GB0223272D0 (en) 2002-10-08 2002-10-08 A protein involved in therapy
GB0223272.6 2002-10-08
PCT/GB2003/004341 WO2004034062A2 (en) 2002-10-08 2003-10-08 Use of cap-1 for the therapy of asthma

Publications (2)

Publication Number Publication Date
AU2003269257A8 true AU2003269257A8 (en) 2004-05-04
AU2003269257A1 AU2003269257A1 (en) 2004-05-04

Family

ID=9945455

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003269257A Abandoned AU2003269257A1 (en) 2002-10-08 2003-10-08 Use of cap-1 for the therapy of asthma

Country Status (3)

Country Link
AU (1) AU2003269257A1 (en)
GB (1) GB0223272D0 (en)
WO (1) WO2004034062A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2011143776A (en) * 2009-03-30 2013-05-10 Протаб Лтд. PROTEIN ASSOCIATED WITH Adenylyl cyclase (CAP1) AND USE IT AS A TARGET FOR IMMUNOMODULATION
US9933424B2 (en) 2011-08-08 2018-04-03 Seoul National University Hospital Human resistin receptor and use thereof
WO2013022262A2 (en) * 2011-08-08 2013-02-14 서울대학교병원 Human resistin receptor, and use thereof
US12410219B2 (en) 2017-01-31 2025-09-09 Seoul National University Hospital Polypeptide derived from CAP1 and pharmaceutical composition comprising same as effective ingredient
KR102040974B1 (en) * 2017-01-31 2019-11-06 서울대학교병원 Polypeptides that were derived from adenylyl cyclase-associated protein 1(CAP1) and pharmaceutical composition comprising the same
CA3170560A1 (en) * 2020-03-02 2021-09-10 Seoul National University Hospital Pharmaceutical composition for lowering blood cholesterol, preventing or treating cardiovascular diseases and reducing inflammation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001271536A1 (en) * 2000-06-29 2002-01-14 Incyte Genomics, Inc. Adenylyl and guanylyl cyclases
AU2002237228A1 (en) * 2000-12-11 2002-06-24 Bayer Aktiengesellschaft Regulation of human adenylate cyclase, type vii
US6706688B2 (en) * 2001-03-09 2004-03-16 Paula Sundstrom Methods for regulating bud-hypha transitions and cAMP levels by the adenylate cyclase-associated protein gene, CAP1
GB0213964D0 (en) * 2002-06-18 2002-07-31 Oxford Glycosciences Uk Ltd Protein

Also Published As

Publication number Publication date
AU2003269257A1 (en) 2004-05-04
WO2004034062A2 (en) 2004-04-22
GB0223272D0 (en) 2002-11-13
WO2004034062A3 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
AU2003288686A8 (en) Compositions and systems for the regulation of genes
AU2003274342A8 (en) Compositions for the treatment of autoimmune disorders
AU2003236991A8 (en) Representations of processes
AU2003225088A8 (en) Regulation of tnf-alpha
EP1556023A4 (en) Nutritional or therapeutic compositions
GB0222945D0 (en) Therapeutic compositions
AU2003282722A8 (en) Therapeutic compositions
EP1379131A4 (en) Regulation of weight
AU2003269257A8 (en) Regulation of cap-1
AU2003250329A8 (en) Regulation of novel human asparagine-hydroxylases
AU2003266271A1 (en) Regulation of human esterase
EP1557670A4 (en) REGULATION OF INTERACTION BETWEEN RAPL AND Rap1
AU2003240174A8 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
AU2003260316A8 (en) Regulation of human hepsin
AU2003271954A8 (en) Regulation of cofilin
AU2003240688A1 (en) Regulation of human kinase
AU2002352253A8 (en) Regulation of human sialyltransferase
AU2003217844A8 (en) Immune regulation
AU2003274328A8 (en) Regulation of mkk3
AU2002231741A1 (en) Regulation of human tau-tubulin kinase
GB0327046D0 (en) Regulation of sperm function
AU2003251665A8 (en) Regulation of human esterase
AU2003287959A8 (en) Regulation of human pde6b
GB0222015D0 (en) Means of assembly-bozz 2
AU2003229785A1 (en) Regulation of human serine/threonine kinase

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase